CancerDrs Find care

Melanoma clinical trials in California

92 actively recruiting melanoma trials at 84 sites across California.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in California:
  • Kaiser Permanente-Anaheim — Anaheim, California
  • Kaiser Permanente-Bellflower — Bellflower, California
  • City of Hope Corona — Corona, California
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • UC San Diego Health System - Encinitas — Encinitas, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of sk…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06246916
Sites in California:
  • Providence Medical Foundation — Fullerton, California
  • Cancer and Blood Specialty Clinic — Los Alamitos, California
  • University of California Los Angeles — Los Angeles, California
  • St. Joseph Hospital Orange — Orange, California
  • Eisenhower Medical Center — Rancho Mirage, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

This is a randomized, controlled, multicenter, open-label Phase 3 clinical study comparing VO in combination with nivolumab versus Physician's Choice treatment for patients with unresectable Stage IIIb-IV cutaneous melanoma whose disease p…

Sponsor: Replimune, Inc.
NCT ID: NCT06264180
Sites in California:
  • UC San Diego Moores Cancer Center — La Jolla, California
  • The Angeles Clinic and Research Institute — Los Angeles, California
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
  • UC Irvine Health, Chao Family Comprehensive Cancer Center — Orange, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a …

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06585410
Sites in California:
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Stanford University — Redwood City, California
  • Peak Dermatology, Aesthetics and Wellness — Visalia, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of treatment with IMA203 administered at the recommende…

Sponsor: Immatics US, Inc.
NCT ID: NCT06743126
Sites in California:
  • City of Hope National Medical Center — Duarte, California
  • UC San Diego Moores Cancer Center — La Jolla, California
  • UCLA Hematology/Oncology — Los Angeles, California
  • UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
  • Stanford Cancer Center — Stanford, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.

Sponsor: Immunocore Ltd
NCT ID: NCT06112314
Sites in California:
  • University of California - San Diego — La Jolla, California
  • The Angeles Clinic and Research Institute- West Los Angeles — Los Angeles, California
  • ESC Norris Comprehensive Cancer Center — Los Angeles, California
  • UCLA Hematology/Oncology — Los Angeles, California
  • Stanford Cancer Institute - Stanford Cancer Center Palo Alto — Palo Alto, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).

Sponsor: Aura Biosciences
NCT ID: NCT06007690
Sites in California:
  • UCSD Shiley Eye Institute, Jacobs Retina Center — La Jolla, California
  • Doris Stein Eye Research Center — Los Angeles, California
  • Stanford University School of Medicine — Palo Alto, California
  • Retinal Consultants Medical Group, Inc. — Sacramento, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Neoadjuvant Darovasertib in Primary Uveal Melanoma

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)

Sponsor: IDEAYA Biosciences
NCT ID: NCT07015190
Sites in California:
  • UCSD Moores Cancer Center — La Jolla, California
  • Jules Stein Eye Institute — Los Angeles, California
  • University of California Irvine Medical Center — Orange, California
  • Stanford Comprehensive Cancer Center — Palo Alto, California
  • Kaiser Permanente-Riverside Medical Center — Riverside, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with im…

Sponsor: Replimune, Inc.
NCT ID: NCT06581406
Sites in California:
  • UC San Diego Moores Cancer Center — La Jolla, California
  • The Angeles Clinic and Research Institute — Los Angeles, California
  • University of California Los Angeles — Los Angeles, California
  • Stanford Cancer Institute — Palo Alto, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unr…

Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT05727904
Sites in California:
  • City of Hope — Duarte, California
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • California Pacific Medical Center — San Francisco, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C/D melanoma patients with …

Sponsor: Philogen S.p.A.
NCT ID: NCT03567889
Sites in California:
  • UC San Diego Moores Cancer Center — La Jolla, California
  • UC Irvine Health-Chao Family Comprehensive Cancer Center — Orange, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread …

Sponsor: Linnaeus Therapeutics, Inc.
NCT ID: NCT06624644
Sites in California:
  • USC Newport Beach — Newport Beach, California
  • UCSF — San Francisco, California
  • Stanford — Stanford, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in California:
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
  • Epic Care-Dublin — Dublin, California
  • Bay Area Breast Surgeons Inc — Emeryville, California
  • Epic Care Partners in Cancer Care — Emeryville, California
  • UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in California:
  • Tower Cancer Research Foundation — Beverly Hills, California
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • The Angeles Clinic and Research Institute - West Los Angeles Office — Los Angeles, California
  • Cedars Sinai Medical Center — Los Angeles, California
  • UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05111574
Sites in California:
  • Sutter Auburn Faith Hospital — Auburn, California
  • Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
  • Palo Alto Medical Foundation-Fremont — Fremont, California
  • Keck Medicine of USC Koreatown — Los Angeles, California
  • Los Angeles General Medical Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in California:
  • Research Site 125 — Los Angeles, California
  • Research Site 133 — Los Angeles, California
  • Research Site 103 — Los Angeles, California
  • Research Site 128 — Santa Monica, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

This phase II trial tests the combination of nivolumab and ipilimumab with sirolimus and prednisone for the treatment of skin (cutaneous) cancer that cannot be removed by surgery (unresectable) or that has spread from where it first starte…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05896839
Sites in California:
  • UC San Diego Moores Cancer Center — La Jolla, California
  • Keck Medicine of USC Koreatown — Los Angeles, California
  • Los Angeles General Medical Center — Los Angeles, California
  • USC / Norris Comprehensive Cancer Center — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifi…

Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT03645928
Sites in California:
  • University of California, San Diego — La Jolla, California
  • University of Southern California — Los Angeles, California
  • University of California, Los Angeles — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types ar…

Sponsor: Vyriad, Inc.
NCT ID: NCT04291105
Sites in California:
  • City of Hope Medical Center — Durate, California
  • USC Norris Comprehensive Cancer Center — Los Angeles, California
  • HOAG Memorial Hospital Presbyterian — Newport Beach, California
  • Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica, California
  • Stanford Health Care — Stanford, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in California:
  • Children's Hospital Los Angeles — Los Angeles, California
  • Children's Hospital of Orange County — Orange, California
  • Lucile Packard Children's Hospital Stanford University — Palo Alto, California
  • UCSF Medical Center-Mission Bay — San Francisco, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in California:
  • Loma Linda University Cancer Center — Loma Linda, California
  • UC Davis Comprehensive Cancer Center — Sacramento, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California:
  • Los Angeles Cancer Network — Los Angeles, California
  • Valkyrie Clinical Trials — Los Angeles, California
  • Pih Health Hematology Medical Oncology — Whittier, California
View on ClinicalTrials.gov →

Showing 25 of 92 trials with sites in California. See all melanoma trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20